Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

EMA panel backs approval of AstraZeneca, Merck & Co.'s PARP inhibitor Lynparza in breast cancer

firstwordpharmaMarch 04, 2019

Tag: EMA , AstraZeneca , Merck , Breast Cancer

PharmaSources Customer Service